$INBX News

Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price

Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?

Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106

Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom

Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT

HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences: The Whole Story Rides On INBRX-106

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma